Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
22.99
+0.72 (3.23%)
Jan 31, 2025, 4:00 PM EST - Market closed
Spyre Therapeutics Employees
Spyre Therapeutics had 30 employees as of December 31, 2023. The number of employees decreased by 39 or -56.52% compared to the previous year.
Employees
30
Change (1Y)
-39
Growth (1Y)
-56.52%
Revenue / Employee
n/a
Profits / Employee
-$7,163,400
Market Cap
1.35B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
SYRE News
- 19 days ago - Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts - PRNewsWire
- 4 weeks ago - Spyre Therapeutics Announces Grants of Inducement Awards - PRNewsWire
- 6 weeks ago - Spyre Therapeutics Added to the Nasdaq Biotechnology Index - PRNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation - Accesswire
- 2 months ago - Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies - PRNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect - Accesswire